Full history for every metric is available with a Kvantra account
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0.0 | 0.0 | 0.0 | 3.1 | 13.9 | 1.7 | 2.3 |
| Operating profit | £m | -8.96 | -3.54 | |||||
| Net profit | £m | -2.41 | -4.96 | -5.85 | -6.51 | 1.29 | -9.07 | -3.67 |
| EPS reported | £ | -0.03 | -0.01 | |||||
| Operating cashflow per share | £ | -0.02 | -0.01 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.02 | -0.01 | |||||
| Free cash flow | £m | -5.58 | -4.80 | |||||
| Net debt | £m | -3.40 | -1.24 | |||||
| Book value equity | £m | 2.80 | 1.99 | |||||
| Book value per share | £ | 0.01 | 0.00 | |||||
| Number of shares | m | 325.97 | 581.33 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.19 | 0.82 | |||||
| P/S LTM | x | 1.96 | 0.70 | |||||
| P/FCF LTM | x | -0.60 | -0.34 | |||||
| EV/EBITDA LTM | x | 0.01 | -0.10 | |||||
| EV/Sales LTM | x | -0.04 | 0.17 | |||||
| Earnings Yield LTM | % | -272.65% | -252.24% | |||||
| FCF Yield | % | -167.63% | -295.24% | |||||
| Quality | ||||||||
| ROE | % | -323.35% | -152.42% | |||||
| ROIC | % | -285.70% | -9.82% | |||||
| Operating margin | % | -528.45% | -9.93% | |||||
| Gross margin | % | 65.89% | 110.59% | |||||
| FCF/Sales | % | -328.70% | -206.86% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -87.82% | -70.66% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.38 | 8.16 | |||||
| EBIT/Net interest | x | - | - | |||||
| Net debt/market cap | % | - | -75.91% | |||||
| Net debt/Equity | x | -1.21 | -0.62 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free